Pharmaceutical News

RSS

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

ISI to host eSolutions Conference in September 2009

Image Solutions Inc. (ISI), a leading provider of electronic submissions management and publishing solutions for the life sciences industry, has unveiled a prestigious line-up of speakers for its annual eSolutions Conference in Barcelona, Spain, this September to support an agenda aimed at reinventing the regulatory function.

10 Aug 2009

Sharing prescription advice among adolescents can have dangerous repercussions

What if a teenager with acne who is taking Accutane - a drug linked to birth defects - gives some to her friend, who is pregnant but does not yet realize it? Unfortunately, this is a realistic scenario.

10 Aug 2009

FDA approves APP Pharmaceuticals' Idarubicin HCI injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.

10 Aug 2009

Expert available on recent FDA analysis of TNF blockers

Lloyd J. Old, M.D., is Director of the Ludwig Institute for Cancer Research (LICR) New York Branch. He is also Director of the Cancer Research Institute (CRI) Scientific Advisory Council, Director of the CRI/LICR Cancer Vaccine Collaborative, and Director of the CRI Cancer Vaccine Consortium. He has been a Member of the National Academy of Sciences since 1978.

9 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Hard To Treat Diseases (HTDS) Chile flu vaccine tender

Hard to Treat Diseases, Inc. subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announced today that the general manager of Mellow Hope paid a visit to Chile, in regards to a significant new business development opportunity related to Mellow Hope's MedVac flu vaccine products. The company intends to participate in a formal tender process to supply a couple separate orders to a couple separate and unrelated entities in Chile.

9 Aug 2009

Sanofi Pasteur submits supplemental application for influenza A(H1N1) 2009 monovalent vaccine to FDA

Sanofi Pasteur announced today the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine.

7 Aug 2009

White House deal with drug industry sparks Democratic revolt

ongressional Democrats are challenging the Obama administration's deal with the pharmaceutical industry to limit how much it would cut prices to contribute to a health care overhaul.

7 Aug 2009

Clinton Foundation reaches deal with Matrix, Pfizer to cut prices for second-line Arvs, TB drug

Former President Bill Clinton on Thursday announced deals with drugmakers Matrix Laboratories and Pfizer to lower the cost of medications to treat patients with drug-resistant forms of HIV/AIDS in the developing world, Reuters reports (Honan, 8/6).

7 Aug 2009

Merck shareholders overwhelmingly approve merger with Schering-Plough

Merck & Co. today announced that its shareholders voted overwhelmingly to approve the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company’s outstanding shares voted in favor of the transaction. Merck today held its special shareholder meeting in Bridgewater, New Jersey to vote on the proposed merger.

7 Aug 2009

H1N1 vaccine will be approved, ready for use by September, WHO says

By September, the first H1N1 (swine) flu vaccines will be approved and ready for use, WHO director of the Initiative for Vaccine Research Marie-Paule Kieny said Thursday, Reuters reports. Kieny also expressed optimism that "vaccine production yields were improving, following a disappointing start that triggered some worries about supplies," the news service writes.

7 Aug 2009

American Oriental Bioengineering launches new product for rhinitis and allergies

American Oriental Bioengineering, Inc. today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.

7 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Obama to drug industry: We still have a deal

"Pressed by industry lobbyists, White House officials on Wednesday assured drug makers that the administration stood by a behind-the-scenes deal to block any Congressional effort to extract cost savings from them beyond an agreed-upon $80 billion," The New York Times reports.

6 Aug 2009

Celera and Aurora to collaborate on cardiovascular genetics

Aurora Health Care, Wisconsin's largest health care provider, and Celera Corporation announced today that they have entered into an agreement to collaborate on the integration of genetic testing aimed at optimizing heart care for Aurora patients

6 Aug 2009

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world.

6 Aug 2009

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Efforts to fast-track the approval of H1N1 (swine) flu vaccines will not compromise the safety or quality controls of vaccine production, the WHO said in a written statement Thursday, the Mail & Guardian reports.

6 Aug 2009

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

6 Aug 2009